港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

海西新药

154.000

-0.900-0.58%

成交量：6.65万

成交额：1,037.09万

市值：121.21亿

市盈率：60.39

高：163.500

开：163.500

低：153.000

收：154.900

52周最高：302.400

52周最低：97.500

股本：7,870.73万

香港流通股本：7,870.73万

量比：11.65

换手率：0.08%

股息：- -

股息率：- -

每股收益(LYR):2.550

净资产收益率：16.58%

总资产收益率：9.23%

市净率：6.20

市盈率(LYR):60.39

市销率: 17.43

数据加载中...

总览公司新闻资讯公告

海西新药(02637)股价下跌9.498%，现价港币$151.5

阿斯达克财经

海西新药9月无新增发行或股份变动

招商证券：海西新药(02637.HK)HX9428有望填补口服治疗nAMD蓝海

招商证券：海西新药(02637)HX9428有望填补口服治疗nAMD蓝海

海西新药2026年中期营收3.12亿元，净利润81.05百万元

海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据

海西新药（02637）公布HX9428治疗nAMD I期及II期阶段性临床数据

海西新药(02637)股价上升5.104%，现价港币$201.8

阿斯达克财经

创新药概念局部走强恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来

港股异动 | 海西新药(02637)涨超3% 近期已递交HX9428的DME IIa期新药临床试验申请

【券商聚焦】国投证券首予海西新药（02637）“买入-A”评级指口服眼药潜力大

海西新药：已提交自研创新药HX9428临床试验申请

海西新药（02637）口服眼底药HX9428完成nAMD一期临床并向NMPA递交DME二期IND

海西新药(02637.HK)：HX9428顺利完成新生血管性年龄相关性黄斑变性(nAMD)之I期临床研究并递交新适应症糖尿病性黄斑水肿(DME)之IIa 期新药临床试验申请(IND)

海西新药8月股本维持不变

海西新药(02637)股价上升8.125%，现价港币$207.6

阿斯达克财经

《业绩》海西新药(02637.HK)中期净利润8,105万人民币倒退24.8%

阿斯达克财经

海西新药(02637.HK)中期净利润为8104.9万元同比减少24.82%

海西新药(02637.HK)发布中期业绩，归母净利润8104.87万元，同比下降24.8%

海西新药2026年中期业绩：营收3.12亿元，净利润0.81亿元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/02637/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":154,"timestamp":1791428705941,"preClose":154.9,"halted":0,"volume":66450,"delay":0,"changeRate":-0.005810200129115595,"floatShares":78707270,"shares":78707270,"eps":2.55,"marketStatus":"交易中","change":-0.9,"latestTime":"10-08 11:06:26","open":163.5,"high":163.5,"low":153,"amount":10370930,"amplitude":0.067786,"askPrice":154.4,"askSize":100,"bidPrice":154,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.305238,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1791432000000},"marketStatusCode":2,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":154.9,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":11.646935,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.55,"volumeRatio":11.646935,"shares":78707270,"dividePrice":0,"high":163.5,"amplitude":0.067786,"preClose":154.9,"low":153,"week52Low":97.5,"pbRate":"6.20","psRate":"17.43","week52High":302.4,"institutionHeld":0,"latestPrice":154,"eps":2.55,"divideRate":0,"volume":66450,"delay":0,"ttmEps":2.305238,"open":163.5,"prevYearClose":136,"prevWeekClose":163,"prevMonthClose":166,"prevQuarterClose":166,"fiveDayClose":166,"twentyDayClose":192.3,"sixtyDayClose":201},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-10-06","current":67.194797,"percent":0.588983,"low":41.43616,"twenty":68.64782,"median":73.160745,"eighty":81.663084,"high":108.687128,"avg":74.776838,"sd":9.190139,"marketCap":13175596998},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270},{"date":"2026-08-28","current":74.907011,"twenty":68.42835,"median":72.201471,"eighty":78.768036,"marketCap":15465978555},{"date":"2026-09-04","current":89.46632,"twenty":68.54394,"median":72.352576,"eighty":79.884165,"marketCap":15686358911},{"date":"2026-09-11","current":86.521471,"twenty":68.545014,"median":72.521094,"eighty":80.616434,"marketCap":15190503110},{"date":"2026-09-18","current":86.274256,"twenty":68.547,"median":72.698486,"eighty":82.359485,"marketCap":15166890929},{"date":"2026-09-25","current":77.153646,"twenty":68.63305,"median":72.884321,"eighty":82.34846,"marketCap":13537650440},{"date":"2026-10-02","current":73.03953,"twenty":68.639584,"median":73.094022,"eighty":81.849555,"marketCap":12829285010},{"date":"2026-10-06","current":74.908416,"twenty":68.64782,"median":73.160745,"eighty":81.663084,"marketCap":13175596998}],"updateTime":1791402008538},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673006202","title":"海西新药(02637)股价下跌9.498%，现价港币$151.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2673006202","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673006202?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 11:14","pubTimestamp":1791342840,"startTime":"0","endTime":"0","summary":"[下跌股]海西新药(02637) 股价在上午11:14比前收市价下跌9.498%，现股价为港币$151.5。至目前为止，今日最高价为$166.7，而最低价为$151.5。总成交量为2000股，总成交金额为港币$31.384万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260929144019863_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260929144019863_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2610071318/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2610071318/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137007572","title":"海西新药9月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1137007572","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137007572?lang=zh_cn&edition=fundamental","pubTime":"2026-10-06 16:39","pubTimestamp":1791275944,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年10月6日发布截至2026年9月30日的证券变动月报表。报告显示，9月期间公司股本保持稳定，未发生新增发行、购回、注销或库藏股变动。同时，公司9月期间无涉及股份期权、权证或可转债相关的发行或变动，也未订立任何其他有待发行股份的协议或安排。本次月报表由联席公司秘书张俊环签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671680295","title":"招商证券：海西新药(02637.HK)HX9428有望填补口服治疗nAMD蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2671680295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671680295?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 13:44","pubTimestamp":1790660665,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1147","02637","BK1191","06099","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671295681","title":"招商证券：海西新药(02637)HX9428有望填补口服治疗nAMD蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2671295681","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671295681?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 13:44","pubTimestamp":1790660665,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，海西新药口服眼底病创新药HX9428有望解决临床治疗痛点，潜在市场空间广阔，首次覆盖给予\"增持\"评级。HX9428作为口服小分子眼底病创新药，无需眼内注射即可发挥治疗作用，可同时覆盖双眼病变，显著降低长期治疗负担，有望为眼底病慢病管理提供全新给药路径，填补口服治疗的空白市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","02637","BK0183","BK1191","06099","BK1564","BK0012","600999","BK0010","BK1147","BK0028","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176753997","title":"海西新药2026年中期营收3.12亿元，净利润81.05百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176753997","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176753997?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 18:13","pubTimestamp":1790244836,"startTime":"0","endTime":"0","summary":"根据公司公告，海西新药在2026年中期录得营收约3.12亿元，同比增长3.8%。同期净利润为81.05百万元，相比上一年同期的107.81百万元下降24.82%。成本结构方面，报告期内营业成本从上一年同期的40.62百万元增至56.46百万元，同比增长39.02%。研发投入则由27.12百万元增加至40.76百万元，同比提高50.32%，约占报告期营收的13.07%。公司在报告期内的经营活动现金流净额为80.56百万元，同比降低30.21%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"海西新药2026年中期营收3.12亿元，净利润81.05百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667834319","title":"海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667834319","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667834319?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 20:26","pubTimestamp":1789561585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，HX9428用于治疗新生血管性年龄相关性黄斑变性的中国I期临床研究已完成24周治疗数据观察;中国II期剂量扩展研究目前仍在进行中，并已取得阶段性临床数据。HX9428中国I期临床研究共纳入15例nAMD患者，覆盖5 mg/QD至40 mg/QD五个剂量组。HX9428中国II期剂量扩展研究目前仍在进行中。公司将持续监测各项安全性指标，并进一步评估HX9428的长期获益风险特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西新药(02637)：HX9428用于治疗nAMD的I期临床研究已完成24周治疗数据观察 II期剂量扩展研究取得阶段性临床数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181985415","title":"海西新药（02637）公布HX9428治疗nAMD I期及II期阶段性临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1181985415","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181985415?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 20:25","pubTimestamp":1789561531,"startTime":"0","endTime":"0","summary":"2026年9月16日，福建海西新药创制股份有限公司发布自愿公告，更新口服小分子候选药物HX9428用于新生血管性年龄相关性黄斑变性的中国I期及II期临床研究进展。截至2026年8月14日，5 mg/QD、10 mg/QD及20 mg/QD三组共入组80例患者，其中约78%为既往接受anti-VEGF治疗患者，约22%为初治患者；45例已完成第13周访视，11例已完成24周治疗。公告提示，HX9428尚未获得任何国家或地区药品监管机构批准上市，临床研究仍在进行中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667722116","title":"海西新药(02637)股价上升5.104%，现价港币$201.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2667722116","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667722116?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 13:05","pubTimestamp":1789535100,"startTime":"0","endTime":"0","summary":"[上升股]海西新药(02637) 股价在下午01:04比前收市价上升5.104%，现股价为港币$201.8。至目前为止，今日最高价为$201.8，而最低价为$192.1。总成交量为2.985万股，总成交金额为港币$586.434万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609161665/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609161665/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617679?lang=zh_cn&edition=fundamental","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","BK1574","LU0348827113.USD","LU2488822045.USD","01177","LU0456846285.SGD","01276","IE00BZ08YS42.EUR","BK0060","LU0588546209.SGD","KURE","LU2097828805.USD","LU0128526141.USD","LU0327786744.USD","LU0417516902.SGD","LU0348825331.USD","LU2097828557.USD","LU1328615791.USD","LU1997244956.HKD","LU0405327148.USD","159992","BK0239","MEDX","600276","LU0043850808.USD","LU1255011170.USD","LU1820825898.SGD","02269","LU0140636845.USD","LU0516423174.USD","LU2039709279.SGD","01477","IBBQ","LU1655091616.SGD","BK1515","IE00B0JY6N72.USD","LU0307460666.USD","LU1023057109.AUD","BK0183","BK0188","LU0359201612.USD","02637","LU1146622755.USD","LU2580892789.USD","LU0516422952.EUR","LU1580142542.USD","09688","LU2148510915.USD","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667148376","title":"港股异动 | 海西新药(02637)涨超3% 近期已递交HX9428的DME IIa期新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2667148376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667148376?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 14:48","pubTimestamp":1789454932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超3%，截至发稿，涨2.89%，报195.5港元，成交额618.26万港元。消息面上，海西新药发布公告，本公司自主研发的创新药项目HXP056的候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。公司表示，将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","IBBJ","BK4585","BMED","KCAI","IBBQ","PSYK","BK4588","VXUS","BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530067","title":"【券商聚焦】国投证券首予海西新药（02637）“买入-A”评级 指口服眼药潜力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530067","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530067?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 14:15","pubTimestamp":1788934513,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，海西新药 核心产品口服VEGFR2小分子HXP056存在颠覆眼底病治疗标准的潜力，有望凭口服优势抢占当前注射眼药市场份额。采用DCF法估值，假设10.0%折现率、2.0%永续增长率，得到公司价值约192.7亿元人民币，对应目标价266.80港元，首次给予买入-A评级。风险提示包括HXP056安全性不及预期、临床开发进度及结果不及预期、产品销售放量不及预期及计算假设不及预期风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991157","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","02637","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新药：已提交自研创新药HX9428临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819950?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MDTX","BK1161","06978","159992","BMED","MEDX","IBBJ","LNGR","BK1191","BK1574","IBBQ","PSYK","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134622913","title":"海西新药（02637）口服眼底药HX9428完成nAMD一期临床并向NMPA递交DME二期IND","url":"https://stock-news.laohu8.com/highlight/detail?id=1134622913","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134622913?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 19:22","pubTimestamp":1788348136,"startTime":"0","endTime":"0","summary":"2026年9月2日，海西新药公布，其自主研发的候选药物HX9428已于2026年8月31日向中国国家药品监督管理局药品审评中心递交糖尿病性黄斑水肿IIa期临床试验申请。该适应症为HX9428推进的第二个开发方向。HX9428为口服小分子药物，拟用于nAMD、DME及视网膜静脉阻塞等血管性视网膜疾病。截至公告日期，HX9428尚未获得任何监管机构上市批准，其安全性与有效性仍需进一步临床验证。公司提醒投资者，创新药研发存在高风险，HX9428能否最终获批上市尚存在不确定性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664355816","title":"海西新药(02637.HK)：HX9428顺利完成新生血管性年龄相关性黄斑变性(nAMD)之I期临床研究并递交新适应症糖尿病性黄斑水肿(DME)之IIa 期新药临床试验申请(IND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664355816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664355816?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 19:18","pubTimestamp":1788347924,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105163555","title":"海西新药8月股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1105163555","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105163555?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 18:11","pubTimestamp":1788343906,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年9月2日发布2026年8月31日止月份的证券变动月报表。公告显示，公司于8月无新增发行、购回或注销股份活动，股本保持稳定。公司表示，其8月末已符合适用的香港联交所规定的最低公众持股量要求。综上所述，截至8月末，公司股本维持不变。本次公告由联席公司秘书张俊环代表公司签署，体现公司遵守香港联交所《上市规则》及相关法规的合规要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664893799","title":"海西新药(02637)股价上升8.125%，现价港币$207.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893799","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664893799?lang=zh_cn&edition=fundamental","pubTime":"2026-09-02 11:32","pubTimestamp":1788319920,"startTime":"0","endTime":"0","summary":"[上升股]海西新药(02637) 股价在上午11:32比前收市价上升8.125%，现股价为港币$207.6。至目前为止，今日最高价为$207.6，而最低价为$188.0。总成交量为7.045万股，总成交金额为港币$1.408千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609021527/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609021527/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663096044","title":"《业绩》海西新药(02637.HK)中期净利润8,105万人民币  倒退24.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663096044","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663096044?lang=zh_cn&edition=fundamental","pubTime":"2026-08-30 23:26","pubTimestamp":1788103560,"startTime":"0","endTime":"0","summary":"海西新药(02637.HK) 公布6月止六个月中期业绩，营业收入3.12亿人民币(下同)，按年增加3.9%。归属股东净利润8,105万元，倒退24.8%，每股收益1.03元。不派息。(d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2026/03/30末期业绩无派息AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20251009084323385_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20251009084323385_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1541943/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1541943/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["MUCmain","UCmain","02637","MCNHmain","CNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662182094","title":"海西新药(02637.HK)中期净利润为8104.9万元 同比减少24.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662182094","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662182094?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 23:07","pubTimestamp":1787929621,"startTime":"0","endTime":"0","summary":"格隆汇8月28日丨海西新药发布截至2026年6月30日止六个月，集团的营业收入约为人民币3.12亿元，同比增长3.85%；净利润为人民币8104.9万元，同比减少24.82%，主要由于子公司生产基地投入使用相比同期产生折旧人民币798.7万元，以及本年度研发费用增加所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260828/32352846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096704","title":"海西新药(02637.HK)发布中期业绩，归母净利润8104.87万元，同比下降24.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662096704?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 21:58","pubTimestamp":1787925522,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151369016","title":"海西新药2026年中期业绩：营收3.12亿元，净利润0.81亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151369016","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151369016?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 20:47","pubTimestamp":1787921254,"startTime":"0","endTime":"0","summary":"海西新药公布截至2026年6月30日止六个月的财务数据显示，期内营收为3.12亿元，同比增长3.85%。同期净利润为0.81亿元，同比下降24.82%。研发投入达0.41亿元，占营收比重约13.08%，同比上升50.32%。本期销售与管理费用合计约1.12亿元，其中销售费用微降0.49%，管理费用增长9.41%。根据财报列示的营业收入与营业成本测算，毛利率约为81.90%，经营利润率约27.05%。海西新药主要业务涵盖创新药分部与仿制药分部。HXP089则获准在中国开展治疗胶质母细胞瘤的临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"海西新药2026年中期业绩：营收3.12亿元，净利润0.81亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":103,"code":"91000000","status":"200"}]}}